BIO Party List

Belgian-US Collaborations in the Immuno-Oncology Gold Rush

8:30 AM–1:00 PM Jun 19, 2017 (America - Los Angeles)

The Westgate Hotel - San Diego 1055 Second Avenue San Diego, CA


Registration open at 8:30
Introduction at 9:30
• Welcome address on behalf of the organizers
• Setting the Scene:
Belgian Academic and Industry Expertise in Immuno-Oncology.

Sessions beginning at 9:45
The promising future of immuno-oncology treatments:

US/Belgian showcases
• ”Clinical trials in oncology : Belgium at the forefront”.
• “From novel immuno-oncology target to pharma alliance: the argenx-AbbVie collaboration”.

Niels P. Emmerich, Ph.D., Senior Director, Head Search and Evaluation Oncology AbbVie,
Debbie Allen, Senior VP Business Development Argenx

• “ Bringing breakthrough pioneering T cell therapies exploiting NK receptors to patients with life-threatening diseases ”

Sophie Agaugue, Manager Research & Development Celyad
Linda L Kelley, PhD Senior Member Moffitt Cancer Center

• “Potent & Scalable active immunotherapies for cancer based on a Plasmacytoid Dendritic Cell line”

Eric Halioua, CEO PDC* Line Pharma

• “Combining the strengths of Pfizer and iTeos to develop novel immunotherapies”

Michel Detheux, CEO iTeos Therapeutics
Denis Patrick, Executive Director, Head, External R&D Innovation, Oncology Research Unit at Pfizer Pharmaceuticals

Moderator: Ann Van Gysel, BioVox

Networking Buffet Lunch from 12:00-1:00

Session ID: 26550